CA2986891C - Compositions for use in treating parkinson's disease and related disorders - Google Patents

Compositions for use in treating parkinson's disease and related disorders Download PDF

Info

Publication number
CA2986891C
CA2986891C CA2986891A CA2986891A CA2986891C CA 2986891 C CA2986891 C CA 2986891C CA 2986891 A CA2986891 A CA 2986891A CA 2986891 A CA2986891 A CA 2986891A CA 2986891 C CA2986891 C CA 2986891C
Authority
CA
Canada
Prior art keywords
disease
parkinson
derivative
methods
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2986891A
Other languages
French (fr)
Other versions
CA2986891A1 (en
Inventor
Nuno AFONSO
Sara SOUSA
Rita VAZ
Diana CHAPELA
Sofia Corte-Real
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LABORATORIO MEDINFAR-PRODUTOS FARMACEUTICOS SA
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Lusomedicamenta SA
Original Assignee
LABORATORIO MEDINFAR-PRODUTOS FARMACEUTICOS SA
Technophage Investigacao e Desenvolvimento em Biotecnologia SA
Lusomedicamenta SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LABORATORIO MEDINFAR-PRODUTOS FARMACEUTICOS SA, Technophage Investigacao e Desenvolvimento em Biotecnologia SA, Lusomedicamenta SA filed Critical LABORATORIO MEDINFAR-PRODUTOS FARMACEUTICOS SA
Publication of CA2986891A1 publication Critical patent/CA2986891A1/en
Application granted granted Critical
Publication of CA2986891C publication Critical patent/CA2986891C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods of treating and managing Parkinson's disease and related disorders. The methods especially find use in managing motor symptoms, including gait problems, particularly during advanced stages when effectiveness of standard medications wear off or side effects become problematic, as seen in Parkinson's disease, other disorders treated with dopaminergic agents, and other conditions associated with motor problems, such as aging or stroke. The treatment also may include disease-modifying effects, neuroprotection of, or neurorescue effects on neuronal cells in patients with Parkinson's disease and other neurodegenerative disorders. In particular, the invention relates to method of administering pharmaceutical compositions comprising effective amounts of tapentadol or a pharmaceutically acceptable salt or derivative thereof or, in other embodiments, stavudine or nabumetone, or a derivative thereof, for treating symptoms associated with Parkinson's disease, either as individual active agents, in combination with each other, or in combination with agents known to treat Parkinson's disease, such as the dopaminergic agent levodopa. The invention also relates to methods of preparing pharmaceutical compositions comprising effective amounts of tapentadol, stavudine, or nabumetone, or a derivative thereof, or further in combination with a dopaminergic agent, or derivative thereof, as well as to methods of using the pharmaceutical compositions in treating Parkinson's disease, related disorders, other conditions treated with dopaminergic agents, and other conditions with gait problems, for example by oral administration of the compositions.
CA2986891A 2015-05-26 2016-05-25 Compositions for use in treating parkinson's disease and related disorders Active CA2986891C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562166531P 2015-05-26 2015-05-26
US62/166,531 2015-05-26
PCT/PT2016/050010 WO2016190766A1 (en) 2015-05-26 2016-05-25 Compositions for use in treating parkinson's disease and related disorders

Publications (2)

Publication Number Publication Date
CA2986891A1 CA2986891A1 (en) 2016-12-01
CA2986891C true CA2986891C (en) 2022-01-04

Family

ID=56322267

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2986891A Active CA2986891C (en) 2015-05-26 2016-05-25 Compositions for use in treating parkinson's disease and related disorders

Country Status (9)

Country Link
US (1) US10471025B2 (en)
EP (1) EP3302454B1 (en)
JP (1) JP6853791B2 (en)
CN (1) CN107660147B (en)
AU (1) AU2016266432B2 (en)
CA (1) CA2986891C (en)
ES (1) ES2869981T3 (en)
PT (1) PT3302454T (en)
WO (1) WO2016190766A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282120B2 (en) * 2018-10-11 2025-08-01 Indivior Uk Ltd Buprenorphine for the treatment of respiratory depression
WO2020139797A1 (en) * 2018-12-24 2020-07-02 Sorrento Therapeutics, Inc. Methods for treating parkinson's disease by administering resiniferatoxin
TW202233169A (en) * 2020-11-10 2022-09-01 瑞典商瑞典綜合研究實驗室公司 A pharmaceutical composition comprising a pharmaceutically acceptable salt of [2-(3-fluoro-5-methanesulfonylphenoxy) ethyl](propyl)amine, and a pharmaceutical drug for parkinson''s disease, and uses of said pharmaceutical composition
BR112023018771A2 (en) * 2021-03-17 2023-10-24 Offxet S R L DEVICE FOR PREDICTING WEAR CONDITIONS IN A PATIENT AFFECTED BY PARKINSON'S DISEASE
CN112933117B (en) * 2021-04-28 2023-04-07 遵义医科大学 Medicine for preventing and/or treating Parkinson's disease and application thereof
KR20240017910A (en) * 2021-06-04 2024-02-08 트랜스포손 테라퓨틱스, 인코포레이티드 LINE-1 inhibitors as cognitive enhancers
CN113422876B (en) * 2021-06-24 2022-05-10 广西电网有限责任公司 AI-based power customer service center auxiliary management method, system and medium
US20250134895A1 (en) * 2021-08-16 2025-05-01 University Health Network Methods and compositions for treating alpha-synuclein-mediated neurodegeneration
CN116832066B (en) * 2023-08-08 2024-01-12 青岛海洋生物医药研究院股份有限公司 Application of sepia ink extract in the preparation of anti-ADHD and anti-depressant drugs

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE4426245A1 (en) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-phenyl-3-dimethylamino-propane compounds with pharmacological activity
ES2286453T3 (en) * 2002-09-17 2007-12-01 Motac Neuroscience Limited TREATMENT OF DYSCINESIA.
AU2007338631A1 (en) 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
RS55769B1 (en) 2007-11-23 2017-07-31 Gruenenthal Gmbh TAPENTADOL COMPOSITIONS
US8969417B2 (en) 2008-06-06 2015-03-03 Pharmatwob Ltd. Pharmaceutical compositions for treatment of Parkinsons disease
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
EP2658523A1 (en) * 2010-12-28 2013-11-06 Euro-Celtique S.A. A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
EP3607943B1 (en) * 2011-04-05 2024-09-11 Grünenthal GmbH Tapentadol for use in treating pain associated with trigeminal neuralgia
US20120277319A1 (en) * 2011-04-29 2012-11-01 Gruenenthal Gmbh Use of Tapentadol for Inhibiting and/or Treating Depression and Anxiety
BR112015023116A2 (en) * 2013-03-15 2017-07-18 Melior Discovery Inc compound, composition, formulation for oral administration, method of treating a disorder, and use of a compound

Also Published As

Publication number Publication date
CN107660147A (en) 2018-02-02
JP2018515549A (en) 2018-06-14
JP6853791B2 (en) 2021-03-31
ES2869981T3 (en) 2021-10-26
AU2016266432B2 (en) 2020-10-22
US20180147160A1 (en) 2018-05-31
US10471025B2 (en) 2019-11-12
EP3302454A1 (en) 2018-04-11
EP3302454B1 (en) 2021-03-10
PT3302454T (en) 2021-04-01
AU2016266432A1 (en) 2017-11-09
CN107660147B (en) 2021-04-30
WO2016190766A1 (en) 2016-12-01
CA2986891A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
WO2016210372A3 (en) Methods to treat neurological diseases
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
EP4631944A3 (en) Rimegepant for cgrp related disorders
PH12018500162A1 (en) 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
PH12012502079A1 (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
MX378579B (en) USE OF PRIDOPIDINE TO IMPROVE COGNITIVE FUNCTION AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2024002360A (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS.
WO2008157747A8 (en) Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
MX2021011269A (en) Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine.
AU2017261303A1 (en) Ophthalmic compositions
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
SI3099307T1 (en) Use of cladribine for treating neuromyelitis optica
CL2020001426A1 (en) Topical ophthalmic composition comprising dobesilic acid to treat diseases of the posterior segment of the eye.
WO2014100679A8 (en) Stimulation and enhancement of regeneration of tissues
WO2016122288A3 (en) Combined formulation including verbenone derivative and therapeutic agent for reperfusion for preventing or treating cerebrovascular diseases, arteriosclerosis or cardiovascular disease
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200306

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250514

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250514